Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507068 | 1.00 | NPC1 (0.49) | NPC1RAB9AMMEGPR132FOLH1 | |
| SCHEMBL7004556 | 1.00 | NPC1 (0.49) | NPC1RAB9AMMEGPR132FOLH1 | |
| SCHEMBL6130478 | 0.86 | MME (0.51) | NPC1RAB9AMMEGPR132CYP1A2 | |
| SCHEMBL7211707 | 0.86 | MME (0.51) | NPC1RAB9AMMEGPR132CYP1A2 | |
| SCHEMBL6130477 | 0.86 | MME (0.51) | NPC1RAB9AMMEGPR132CYP1A2 | |
| SCHEMBL2559773 | 0.85 | GAA (0.50) | NPC1RAB9AMMEFOLH1 | |
| SCHEMBL2559768 | 0.85 | GAA (0.50) | NPC1RAB9AMMEFOLH1 | |
| SCHEMBL8702185 | 0.83 | MME (0.52) | NPC1RAB9AMMEGPR132FOLH1 | |
| SCHEMBL10610612 | 0.82 | FOLH1 (0.60) | NPC1RAB9AMMEFOLH1 | |
| SCHEMBL10734377 | 0.82 | NPC1 (0.45) | NPC1RAB9AGPR132FOLH1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153034-B1 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2007-10-17 | — | — | EP | disclosed |
| US-6992097-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050143318-A1 | Growth hormone secretagogues | DODGE JEFFREY A (US) | 2005-06-30 | — | — | US | disclosed |
| US-6828331-B1 | Non-peptidyl in nature and are, therefore, more metabolically stable than growth hormone, growth hormone releasing hormone, or analogs of either of these proteins | ELI LILLY AND COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-20040122234-A1 | Growth Hormone secretagogues | HAUSER KENNETH LEE (US) | 2004-06-24 | — | — | US | disclosed |
| US-6639076-B1 | Such as 2-(2-amino-2-methylpropanoylamino)-n-(1-(2-oxo-1-phenyl-2-pyrrolidinylethyl -4-yl)-4-phenylbutanamide | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1112071-A4 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6329342-B1 | CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2001-12-11 | — | — | US | disclosed |
| EP-1153034-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1112071-A1 | GROWTH HORMONE SECRETAGOGUES | Eli Lilly & Company (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000049037-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000010565-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0933365-A2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0898963-A2 | Congestive heart failure treatment | ELI LILLY AND COMPANY (US) | 1999-03-03 | — | — | EP | disclosed |
| WO-1999008697-A1 | TREATMENT OF CONGESTIVE HEART FAILURE WITH GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999008699-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143318-A1 | Growth hormone secretagogues | GHSR, GHRHR, SSTR3 | NPC1 2703/4885RAB9A 4295/4885MME 725/4885 |
| US-20040122234-A1 | Growth Hormone secretagogues | GHSR, GHRHR, CRH | NPC1 3004/4885RAB9A 2778/4885MME 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.